C Capparelli
Overview
Explore the profile of C Capparelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
5621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kostenuik P, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, et al.
Endocrinology
. 2001 Sep;
142(10):4295-304.
PMID: 11564687
PTH is a potent bone anabolic factor, and its combination with antiresorptive agents has been proposed as a therapy for osteoporosis. We tested the effects of PTH, alone and in...
2.
Morony S, Capparelli C, Sarosi I, Lacey D, Dunstan C, Kostenuik P
Cancer Res
. 2001 Jun;
61(11):4432-6.
PMID: 11389072
Certain malignancies, including breast cancer, frequently metastasize to bone, where the tumor cells induce osteoclasts to locally destroy bone. Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor family,...
3.
Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, et al.
Mol Ther
. 2001 Mar;
3(2):197-205.
PMID: 11237676
Osteoprotegerin (OPG) regulates bone resorption by inhibiting osteoclast formation, function, and survival. The current studies employed a mouse ovariectomy (OVX) model of estrogen deficiency to investigate gene therapy with OPG...
4.
Min H, Morony S, Sarosi I, Dunstan C, Capparelli C, Scully S, et al.
J Exp Med
. 2000 Aug;
192(4):463-74.
PMID: 10952716
High systemic levels of osteoprotegerin (OPG) in OPG transgenic mice cause osteopetrosis with normal tooth eruption and bone elongation and inhibit the development and activity of endosteal, but not periosteal,...
5.
Capparelli C, Kostenuik P, Morony S, Starnes C, Weimann B, Van G, et al.
Cancer Res
. 2000 Mar;
60(4):783-7.
PMID: 10706080
Osteoprotegerin (OPG), a novel, secreted tumor necrosis factor receptor family member that inhibits osteoclast formation and activity was examined for its activity in a syngeneic tumor model of humoral hypercalcemia...
6.
Li J, Sarosi I, Yan X, Morony S, Capparelli C, Tan H, et al.
Proc Natl Acad Sci U S A
. 2000 Mar;
97(4):1566-71.
PMID: 10677500
We have generated RANK (receptor activator of NF-kappaB) nullizygous mice to determine the molecular genetic interactions between osteoprotegerin, osteoprotegerin ligand, and RANK during bone resorption and remodeling processes. RANK(-/-) mice...
7.
Kong Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al.
Nature
. 1999 Dec;
402(6759):304-9.
PMID: 10580503
Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG). In addition, OPGL regulates...
8.
Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey D, et al.
J Bone Miner Res
. 1999 Sep;
14(9):1478-85.
PMID: 10469275
Osteoprotegerin (OPG) is a secreted protein that inhibits osteoclast formation and activity and appears to be a critical regulator of bone mass and metabolism. In the current study, mice were...
9.
Burgess T, Qian Y, Kaufman S, Ring B, Van G, Capparelli C, et al.
J Cell Biol
. 1999 May;
145(3):527-38.
PMID: 10225954
Osteoprotegerin (OPG) and OPG-ligand (OPGL) potently inhibit and stimulate, respectively, osteoclast differentiation (Simonet, W.S., D.L. Lacey, C.R. Dunstan, M. Kelley, M.-S. Chang, R. Luethy, H.Q. Nguyen, S. Wooden, L. Bennett,...
10.
Lomaga M, Yeh W, Sarosi I, Duncan G, Furlonger C, Ho A, et al.
Genes Dev
. 1999 Apr;
13(8):1015-24.
PMID: 10215628
Bone resorption and remodeling is an intricately controlled, physiological process that requires the function of osteoclasts. The processes governing both the differentiation and activation of osteoclasts involve signals induced by...